The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis

BACKGROUND: Immunotherapy has become an essential part of cancer treatment after showing great efficacy in various malignancies. However, its effectiveness in pancreatic ductal adenocarcinoma (PDAC), especially in resectable pancreatic cancer, has not been studied. The primary objective of this stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Amin, Saber, Baine, Michael, Meza, Jane, Lin, Chi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285784/
https://www.ncbi.nlm.nih.gov/pubmed/32517661
http://dx.doi.org/10.1186/s12885-020-07016-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285784/
https://www.ncbi.nlm.nih.gov/pubmed/32517661
http://dx.doi.org/10.1186/s12885-020-07016-8

Ejemplares similares